| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2702b587e5cc98a386407912b42f723c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-96486
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-085 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-573
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-573
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6883 |
| filingDate |
2022-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a3ba574ac48e3667127e40abcdea6c51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3aa8024227b3b3fa8f419a18958203fb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_159bf862b3526e63414fa8732f18e241
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e93697b69a06c9868a305439ec4907b7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4ff6fc2024913624e158e38692bc14da
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f03240a315ebd0926d907a2593ad22f6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a37ee7ed16febd408cb9901dea9ff355 |
| publicationDate |
2022-09-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-114994317-A |
| titleOfInvention |
Application of metalloprotease ADAMTS4 in the preparation of early hepatic fibrosis drugs |
| abstract |
The invention discloses the application of a metalloprotease ADAMTS4 in the preparation of early stage liver fibrosis drugs, and belongs to the field of biopharmaceuticals. The invention discloses the application of a metalloprotease ADAMTS4 as an action target in preparing a drug for treating early liver fibrosis. The ADAMTS4 is knocked out or ADAMTS4 expression is inhibited to play a role in treating early liver fibrosis. The experimental results show that ADAMTS4 deletion Afterwards, it can activate the expression of TGF-β1 to promote collagenase synthesis and inhibit the activity of hepatic stellate cells to achieve the effect of slowing down liver fibrosis. The present invention finds that it has the feasibility of delaying, stopping and reversing the development of liver fibrosis by inhibiting the activity of ADAMTS4 protein. It provides a theoretical basis and molecular means for the treatment of related diseases, and provides new ideas for the control of early liver fibrosis in liver cancer. |
| priorityDate |
2022-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |